Back

All-cause mortality of patients with STEMI, cardiogenic shock and multivessel coronary disease treated with culprit vessel only versus multivessel primary PCI.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: STEMI Primary Percutaneous Coronary Intervention (PCI) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ota Hlinomaz

St. Anne University Hospital Brno (FNUSA), Brno (Czechia)

6 More presentations in this session

Presentation thumbnail
The vascular response to ultrathin biodegradable polymer sirolimus-eluting stent at 2-weeks and 1-year follow up in patients with ST-elevation myocardial infarction
Doctor Y. Oishi (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Reperfusion strategy and late clinical outcomes of patients with ST-elevation myocardial infarction (STEMI) in the absence of standard modifiable risk factors (SMuRFs)
Professor J. French (Sydney, AU)
Abstract Slides
Presentation thumbnail
Deferred stent implantation in patients with ST segment elevation myocardial infarction with high thrombus burden
Doctor M. Mohamady (Benha, EG)
Abstract Slides
Presentation thumbnail
Impact of age at the time of the first ST-elevation myocardial infarction on 10-year outcomes. A sub-analysis from the EXAMINATION EXTEND trial
Doctor V. Arevalos Rivas (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Predictors of no-reflow in patients with myocardial infarction and ST-segment elevation treated with primary angioplasty
Doctor A. Cordero (Alicante, ES)
Abstract Slides

Access the full session

Session thumbnail
STEMI

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Association of PCI with outcomes in stable coronary artery disease
thumbnail
Congress Presentation
Optimal medical therapy or revascularisation: how new data should change our practice?
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources